menu
    • menu
    [{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Scenic Biotech","amount2":0.38,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0.38,"dosageForm":"","sponsorNew":"Scenic Biotech \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"Scenic Biotech \/ Genentech"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Barth Syndrome Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Scenic Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Scenic Biotech \/ Barth Syndrome Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Scenic Biotech \/ Barth Syndrome Foundation"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"NICHD","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Scenic Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scenic Biotech \/ NICHD","highestDevelopmentStatusID":"2","companyTruncated":"Scenic Biotech \/ NICHD"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"SC-2882","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Scenic Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Scenic Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scenic Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Scenic Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Scenic Biotech \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Scenic Biotech \/ Bristol Myers Squibb"}]

    Find Clinical Drug Pipeline Developments & Deals by Scenic Biotech

    Menu

    Scenic Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Scenic Biotech

                            Netherlands arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Scenic Biotech

                            Netherlands arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb

                            Details : Under the collaboration, Bristol Myers Squibb gains access to Scenic’s Cell-Seq technology platform to unlock the underlying genetic interactions of cellular pathways for undisclosed targets.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 30, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Scenic Biotech

                            Netherlands arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Scenic Biotech

                            Netherlands arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SC-2882

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeuti...

                            Details : SC-2882 is a Scenic’s first-in-class QPCTL inhibitor, it is curently in preclinical stage where it is being evaluated as a new potential treatment approach for diffuse large B-cell lymphoma (DLBCL).

                            Brand Name : SC-2882

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 09, 2023

                            Lead Product(s) : SC-2882

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Scenic Biotech

                            Netherlands arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Scenic Biotech

                            Netherlands arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Discovery

                            Sponsor : NICHD

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for ...

                            Details : CRADA combines Scenic Biotech’s genetic modifier platform with NIH’s patient registry to unlock genetic modifiers as a path to novel therapies for NPC disease. The goal of the collaboration is to obtain clinical insights into genes that can reduce th...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 01, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Discovery

                            Sponsor : NICHD

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Scenic Biotech

                            Netherlands arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Scenic Biotech

                            Netherlands arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery

                            Sponsor : Barth Syndrome Foundation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to a Find T...

                            Details : Both companies, aim to identify small molecule drugs to treat Niemann Pick Type C (NP-C), a rare lipid storage disorder that affects lipid metabolism, a second undisclosed program to treat a severe heritable metabolic syndrome, and Barth syndrome program...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 30, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery

                            Sponsor : Barth Syndrome Foundation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Scenic Biotech

                            Netherlands arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Scenic Biotech

                            Netherlands arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery

                            Sponsor : Genentech

                            Deal Size : $375.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech

                            Details : Under the terms of the agreement, Scenic will utilize its Cell-Seq platform and its data warehouse of genetic modifiers to identify drug targets in multiple therapeutic areas.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 21, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery

                            Sponsor : Genentech

                            Deal Size : $375.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth